Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Dexcom (DXCM) over the last 16 years, with Q4 2025 value amounting to $17.8 million.

  • Dexcom's Change in Inventory rose 15443.43% to $17.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $63.7 million, marking a year-over-year increase of 61370.97%. This contributed to the annual value of $63.7 million for FY2025, which is 61370.97% up from last year.
  • Dexcom's Change in Inventory amounted to $17.8 million in Q4 2025, which was up 15443.43% from $33.6 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Change in Inventory ranged from a high of $78.6 million in Q3 2023 and a low of -$32.7 million during Q4 2024
  • Its 5-year average for Change in Inventory is $18.3 million, with a median of $18.2 million in 2025.
  • As far as peak fluctuations go, Dexcom's Change in Inventory tumbled by 22396.31% in 2022, and later surged by 513636.36% in 2023.
  • Quarter analysis of 5 years shows Dexcom's Change in Inventory stood at $6.0 million in 2021, then plummeted by 195.0% to -$5.7 million in 2022, then skyrocketed by 1135.09% to $59.0 million in 2023, then plummeted by 155.42% to -$32.7 million in 2024, then surged by 154.43% to $17.8 million in 2025.
  • Its Change in Inventory stands at $17.8 million for Q4 2025, versus $33.6 million for Q3 2025 and $18.5 million for Q2 2025.